ALCLS pivots to in vivo gene editing programs
ALCLS says it is shifting focus to in vivo gene editing and advancing HEAL-101 and HEAL-201 for severe lipid disorders, while discontinuing internal cell therapy programs and extending cash runway into 2028.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.